SNA 125

Drug Profile

SNA 125

Alternative Names: CT 340; SNA 125

Latest Information Update: 19 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Creabilis SA
  • Developer Creabilis SA; Sienna Biopharmaceuticals
  • Class Analgesics; Anti-inflammatories; Antipsoriatics; Polyethylene glycols; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 3 inhibitors; MAP2K3 protein inhibitors; TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Atopic dermatitis; Pruritus; Psoriasis
  • Discontinued Arthritis; Neuropathic pain; Pain; Scars

Most Recent Events

  • 12 Mar 2018 Sienna Biopharmaceuticals initiates enrolment in a phase I/II trial for Pruritus (associated with atopic dermatitis) in USA
  • 12 Mar 2018 Phase-I/II clinical trials in Atopic dermatitis in USA (Topical)
  • 14 Feb 2018 Phase-I/II clinical trials in Pruritus (associated with psoriasis) in USA (Topical) (Sienna Biopharmaceuticals pipeline, March 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top